DE69635207D1 - Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist. - Google Patents

Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist.

Info

Publication number
DE69635207D1
DE69635207D1 DE69635207T DE69635207T DE69635207D1 DE 69635207 D1 DE69635207 D1 DE 69635207D1 DE 69635207 T DE69635207 T DE 69635207T DE 69635207 T DE69635207 T DE 69635207T DE 69635207 D1 DE69635207 D1 DE 69635207D1
Authority
DE
Germany
Prior art keywords
disease
alzheimer
chromosome
gene product
whose gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635207T
Other languages
English (en)
Other versions
DE69635207T2 (de
Inventor
Ephrat Levy-Lahad
E Tanzi
D Schellenberg
Wilma Wasco
D Bird
John Mulligan
J Galas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Darwin Molecular Corp
Original Assignee
EPHRAT LEVY-LAHAD
VA MEDICAL CENTER SEATTLE
EPHRAT LEVY LAHAD
VA MEDICAL CT SEATTLE
General Hospital Corp
Darwin Molecular Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EPHRAT LEVY-LAHAD, VA MEDICAL CENTER SEATTLE, EPHRAT LEVY LAHAD, VA MEDICAL CT SEATTLE, General Hospital Corp, Darwin Molecular Corp filed Critical EPHRAT LEVY-LAHAD
Publication of DE69635207D1 publication Critical patent/DE69635207D1/de
Application granted granted Critical
Publication of DE69635207T2 publication Critical patent/DE69635207T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69635207T 1995-07-07 1996-07-05 Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist. Expired - Lifetime DE69635207T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US95695P 1995-07-07 1995-07-07
US956P 1995-07-07
US167595P 1995-07-28 1995-07-28
US1675P 1995-07-28
US217495P 1995-08-11 1995-08-11
US2174P 1995-08-11
US232895P 1995-08-14 1995-08-14
US2328P 1995-08-14
PCT/US1996/011386 WO1997003192A2 (en) 1995-07-07 1996-07-05 Chromosome 1 gene and gene products related to alzheimer's disease

Publications (2)

Publication Number Publication Date
DE69635207D1 true DE69635207D1 (de) 2006-02-02
DE69635207T2 DE69635207T2 (de) 2006-06-22

Family

ID=27485043

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635207T Expired - Lifetime DE69635207T2 (de) 1995-07-07 1996-07-05 Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist.

Country Status (7)

Country Link
US (2) US6468791B1 (de)
EP (2) EP0846171B1 (de)
JP (3) JP4073955B2 (de)
AT (1) ATE305039T1 (de)
CA (1) CA2226255A1 (de)
DE (1) DE69635207T2 (de)
WO (1) WO1997003192A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5379119B2 (ja) * 1995-04-28 2013-12-25 エイチエスシー リサーチ アンド ディベロップメント リミテッド アルツハイマー病に関連する遺伝子配列およびタンパク質、ならびにその使用
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6210919B1 (en) 1995-04-28 2001-04-03 Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6531586B1 (en) 1995-04-28 2003-03-11 The Hospital For Sick Children Genetic sequences related to Alzheimer's Disease
EP0846172A2 (de) * 1995-08-16 1998-06-10 The President And Fellows Of Harvard College Verfahren zur identifizierung von genen, die für das nicht-trennen von chromosomen hervorrufen
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
ES2128265B1 (es) * 1997-06-04 2000-03-01 Euroespes S A Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
WO1999035501A1 (en) 1998-01-09 1999-07-15 The Governing Council Of The University Of Toronto Presenilin protein interactions
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
JP2003018991A (ja) * 2001-06-27 2003-01-21 Japan Science & Technology Corp プレセニリン−２遺伝子エキソン５欠損型スプライシング異常の生成に関与する核酸
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CA2654711C (en) * 2006-06-12 2015-01-06 Car-Ber Investments Inc. Nozzle testing apparatus and method
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2182983B1 (de) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Behandlung von amyloidogenen erkrankungen mittels humanisierter anti-abeta antikörper
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN104011192B (zh) * 2011-12-20 2017-08-25 荷兰联合利华有限公司 包含去污聚合物的各向同性液体洗涤剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210919B1 (en) * 1995-04-28 2001-04-03 Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease

Also Published As

Publication number Publication date
US6468791B1 (en) 2002-10-22
JP2001517922A (ja) 2001-10-09
JP2008035862A (ja) 2008-02-21
WO1997003192A2 (en) 1997-01-30
ATE305039T1 (de) 2005-10-15
EP0846171A2 (de) 1998-06-10
WO1997003192A3 (en) 1997-04-03
JP4073955B2 (ja) 2008-04-09
DE69635207T2 (de) 2006-06-22
CA2226255A1 (en) 1997-01-30
JP2008035863A (ja) 2008-02-21
EP0846171B1 (de) 2005-09-21
US20030180880A1 (en) 2003-09-25
EP1637600A1 (de) 2006-03-22

Similar Documents

Publication Publication Date Title
DE69635207D1 (de) Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist.
ATE315087T1 (de) Neuartige auf p53 ansprechende gene
Coen et al. Construction of hybrid proteins that migrate retrogradely and transynaptically into the central nervous system
EP1439230A3 (de) Menschliche transmembranprotein TMP-2 gen
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
CY1107552T1 (el) Ly6h γονιδιο
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
FI925986A0 (fi) Slumpartat bio-oligomer bibliotek, ett foerfarande foer syntetisering avdet samt ett foerfarande foer anvaendning av det
NO179412C (no) Hybrid DNA-molekyl som koder for fibronektinbindende protein, mikroorganismer inneholdende slike DNA-molekyler samt fremgangsmåte ved fremstilling av slikt protein
DE69434844D1 (de) Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
PT648836E (pt) Transactivador do mhc de classe ii (ciita) e suas utilizacoes
ZA98656B (en) Lage-1 tumer associated nucleic acids
WO2000058339A3 (en) 50 human secreted proteins
WO2000043495A3 (en) 33 human secreted proteins
WO2000061624A8 (en) 48 human secreted proteins
ATE236977T1 (de) Verwendung einer rekombinanten dna für die herstellung eines medikaments, wobei die rekombinante dna eine dna umfasst, die die sm1- isoform des proteins der schweren kette von myosin der glatten muskulatur codiert
WO2000061596A8 (en) 50 human secreted proteins
WO2000058340A3 (en) 50 human secreted proteins
MX9801603A (es) Alteraciones geneticas relacionadas con la enfermedad de alzheimer hereditaria.
ATE319821T1 (de) Verfahren und produkt zur regulation der reaktionsempfindlichkeit von zellen auf externe signale
BR9810643A (pt) Genes e proteìnas de telomerase de vertebrado, eutilização dos mesmos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DARWIN MOLECULAR CORP., BOTHELL, WA., US

Owner name: THE GENERAL HOSPITAL CORP., BOSTON, MASS., US